# Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases

> **NCT07413952** · PHASE2 · NOT_YET_RECRUITING · sponsor: **The First Affiliated Hospital of Guangzhou Medical University** · enrollment: 45 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** Limertinib Plus Radiotherapy

## Key facts

- **NCT ID:** NCT07413952
- **Lead sponsor:** The First Affiliated Hospital of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07413952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07413952, "Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07413952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*